Close Menu

kidney disease

Metabolon will work with Johns Hopkins University and Tufts Medical Center to develop and clinically validate the new blood-based diagnostic.

In PLOS this week: NEK8 mutations in a ciliopathy disorder, characterization of the tea species Camellia sinensis, and more.

Researchers from the University of Michigan are beginning to use Drop-Seq to characterize human kidney cells.

With data from the CanPREDDICT study, the partners will develop a test to predict the rate of disease progression in patients with chronic kidney disease.

In PLOS this week: gene expression differences in plants susceptible to or resistant to Plum pox virus, novel human pegivirus, and more.

Using transcripts expressed in kidney tissue as a guide, researchers identified a protein marker of chronic kidney disease progression and kidney function in urine.

Clinicians in the hospital will use IBM's Watson to identify possible options for diagnosing and treating rare pediatric diseases starting with kidney disease.

Researchers have sequenced and analyzed more than 50 feral and domestic cats in search of genetic variants involved in specific physical features and forms of disease. 

SGI will use unique DNA design, DNA synthesis, genome editing, and genome modification tools to develop engineered primary pig cells with modified genomes. 

Researchers detected new and known kidney stone risk genes through a genome-wide association study involving thousands of Icelanders.

Pages

The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.

The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.

News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.

In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.